ANP also advises that subsequent to the Company’s trading halt, a Pharmaceutical Company that has
previously expressed an interest in ATL103 has indicated to ANP its desire to move into licensing due
diligence. While ANP is entertaining this interest from the Pharmaceutical Company, it has not
committed to partnering ATL1103 at this stage of the drug’s development and will continue its
planning to progress ATL1103’s development towards a Phase II clinical trial.
atl1103 successfully progresses towards phase , page-2
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.2¢ |
Change
-0.003(3.53%) |
Mkt cap ! $85.01M | |||
| Open | High | Low | Value | Volume |
| 8.5¢ | 8.6¢ | 8.2¢ | $103.7K | 1.237M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 204084 | 8.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.5¢ | 280000 | 3 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| PER (ASX) Chart |